Assignee profile:

PhaseBio Pharmaceuticals, Inc.

City:

Malvern, Pennsylvania

Country:

United States

Published Applications:

17

Last publication date:

2021-03-11

Patent Grants:

11

Last grant date:

2022-03-08

Top Inventors for applications by PhaseBio Pharmaceuticals, Inc.

These are the the leading inventors for applications assigned to PhaseBio Pharmaceuticals, Inc.:

Recent patent applications by PhaseBio Pharmaceuticals, Inc.

PhaseBio Pharmaceuticals, Inc. based in Malvern, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2021-03-11 ✅ Patent 11,266,719 granted on 2022-03-08
US20210069299A1
Human necessities

Methods and compositions for treating muscle disease and disorders

#2 | 2020-12-17 ✅ Patent 11,136,309 granted on 2021-10-05
US20200392112A1
Chemistry; metallurgy

Metalloenzyme inhibitor compounds

#3 | 2019-01-17 ✅ Patent 10,722,590 granted on 2020-07-28
US20190015523A1
Human necessities

ELP fusion proteins for controlled and sustained release

#4 | 2019-01-10 ✅ Patent 11,040,034 granted on 2021-06-22
US20190008861A1
Human necessities

Metalloenzyme inhibitor compounds

#5 | 2018-11-22 ✅ Patent 10,688,156 granted on 2020-06-23
US20180333467A1
Human necessities

Methods and compositions for treating muscle disease and disorders

#6 | 2017-06-29 ✅ Patent 11,052,132 granted on 2021-07-06
US20170182130A1
Human necessities

Methods and compositions for treating cystic fibrosis

#7 | 2017-05-18 ✅ Patent 9,919,032 granted on 2018-03-20
US20170136092A1
Human necessities

Method for administering a sustained release formulation

#8 | 2017-03-16 ✅ Patent 10,940,182 granted on 2021-03-09
US20170072021A1
Human necessities

Use of modified vasoactive intestinal peptides in the treatment of hypertension

#9 | 2016-08-04 ✅ Patent 9,700,598 granted on 2017-07-11
US20160220642A1
Human necessities

Modified vasoactive intestinal peptides

#10 | 2015-04-23 ✅ Patent 9,561,262 granted on 2017-02-07
US20150111829A1
Human necessities

Use of modified vasoactive intestinal peptides in the treatment of hypertension

#11 | 2015-04-23
US20150111816A1
Chemistry; metallurgy

METHODS AND TREATMENT WITH GLP-1 RECEPTOR AGONISTS

#12 | 2014-06-19
US20140171370A1
Human necessities

FORMULATIONS OF ACTIVE AGENTS FOR SUSTAINED RELEASE

#13 | 2013-07-11
US20130178416A1
Human necessities

FUSION PEPTIDE THERAPEUTIC COMPOSITIONS

#14 | 2013-06-13
US20130150291A1
Human necessities

THERAPEUTIC AGENTS COMPRISING INSULIN AMINO ACID SEQUENCES

#15 | 2013-06-06
US20130143802A1
Human necessities

FUSION PEPTIDE THERAPEUTIC COMPOSITIONS

#16 | 2013-04-04
US20130084277A1
Human necessities

FORMULATIONS OF ACTIVE AGENTS FOR SUSTAINED RELEASE

#17 | 2011-07-21 ✅ Patent 9,029,505 granted on 2015-05-12
US20110178017A1
Human necessities

Modified vasoactive intestinal peptides

Also check out PHASEBIO PHARMACEUTICALS, INC.'s (Malvern, United States) applicant profile with 9 patent applications submitted.

AssigneeID:

16762 ⎘